Results 51 to 60 of about 2,191 (125)

Activation of the AKT-mTOR pathway confers selpercatinib resistance in thyroid cancer cells harboring the CCDC6-RET fusion gene

Biochemistry and Biophysics Reports
Treatment strategies based on genetic alterations have been recently developed for the treatment of advanced or metastatic thyroid cancer. RET inhibitors are used to treat thyroid cancer with rearranged during transfection (RET) gene alterations; however,
Masatsugu Amitani, Tadafumi Shimizu, Takaaki Oba, Masaki Kawamura, Ken-ichi Ito   +4 more
doaj   +1 more source

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis

JTO Clinical and Research Reports
Introduction: Selpercatinib’s consistent efficacy and manageable safety profile were observed in patients with RET fusion–positive NSCLC across geographies in single-arm studies (LIBRETTO-001 and LIBRETTO-321).
Koichi Goto, MD, PhD, Herbert H. Loong, M.B.B.S., Caicun Zhou, MD, PhD, Kazumi Nishino, MD, PhD, Dae Ho Lee, MD, PhD, Se-Hoon Lee, MD, James Chih-Hsin Yang, MD, PhD, Dan Liu, PhD, Minji Kim Uh, PhD, Hongmei Han, MS, MAS, Tarun Puri, MD, Aimee Bence Lin, PhD, Ying Cheng, MD   +12 more
doaj   +1 more source

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero, Niall Prendiville, Tatiana Cazorla, Maria Baena‐Nuevo, Röhm Sandra, Emilio Camafeita, Stefan Knapp, Patricia Alfonso   +7 more
wiley   +1 more source

Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib

European Thyroid Journal
Highly selective RET inhibitor selpercatinib has demonstrated notable efficacy in advanced/progressive RET-mutant medullary thyroid cancer (MTC) patients.
Carla Gambale, Alessandro Prete, Chiara Romei, Alessandro Celi, Rossella Elisei, Antonio Matrone   +5 more
doaj   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Molecular Diagnostics in Thyroid Nodules: Current Applications, Clinical Value, and Future Perspective

Med Research, Volume 2, Issue 2, Page 204-213, June 2026.
ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao, Min Ding, Zhixue Min, Yihan Dong, Xuanye Cao, Qiang Lu, Cong Chen, Yahui Wu, Xin Guo, Zhen Wu, Jing Xie, Dan Xu, Haizhen Chen, Rongli Xie, Jian Fei   +14 more
wiley   +1 more source

Neoadjuvant Selpercatinib for Stage IIIA Primary Pulmonary Adenocarcinoma With RET Fusion: A Case Report

Respirology Case Reports
Selpercatinib represents the first targeted therapeutic agent approved for RET fusion‐positive unresectable non‐small cell lung cancers. This case report describes a patient with stage IIIA (cT2aN2M0) RET fusion‐mutated adenocarcinoma of the left upper ...
Zihan Cui, Yizhuo Hu, Jun Zhao, Chuanyong Mu, Chang Li   +4 more
doaj   +1 more source

Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report

JTO Clinical and Research Reports
RET fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a CCDC6::RET fusion treated with selpercatinib ...
Jacobi B. Hines, MD, Benjamin C. Bowar, PharmD, Margaret Colleton, MMS, Lydia Chelala, MD, Peng Wang, MD, Angad A. Chadha, MD, Jeremy Segal, MD, Christine M. Bestvina, MD   +7 more
doaj   +1 more source

Selpercatinib: A narrative drug review

Cancer Research, Statistics, and Treatment
Rearranged during transfection (RET) alteration promotes oncogenesis in a few cancers. RET mutation positivity is seen in approximately 70% of medullary thyroid cancers, around 30% of differentiated papillary thyroid cancers, and 1-2% of non-small-cell ...
Priyadarshini Eashwar Raj, Rekabtala Bhaskar, Srikanth Anne   +2 more
doaj   +1 more source

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

Frontiers in Oncology
Over the past decade, molecular characterization has led to change the management of advanced non-small cell lung cancer (NSCLC) harboring driver mutations.
Elisa De Carlo, Elisa Bertoli, Elisa Bertoli, Monica Schiappacassi, Brigida Stanzione, Alessandro Del Conte, Roberto Doliana, Michele Spina, Alessandra Bearz   +8 more
doaj   +1 more source